Therefore, exploring the interaction of TNF-α and MMP-2 in patients with TRS and chronic medicated schizophrenia (CMS) could provide insight into the mechanisms driving treatment resistance and chronicity. This evidence concerns the gene MMP2 and schizophrenia.